SLE-associated acute transverse myelitis (ATM) is a rare, but potentially severe complication of Systemic lupus erythematosus (SLE), and may lead to significant motor, sensory and autonomic dysfunctions in the central nervous system resulting in marked neurological deficits. It is important to recognize its clinical feature to allow timely diagnosis and management of this condition. In this review, we aimed to provide the reader with the understanding of its clinical presentation and classification, the underlying pathological, MRI (magnetic resonance imaging) appearance, and current status of management, with an emphasis on recent discoveries and advancements.
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included ischemic necrosis, infarction or malacia in 8 cases, vasculitis without necrotic foci in 2 cases and degenerative lesions within the white matter with adventitia thickening in small arteries in 1 case. Vascular pathologies included perivascular lymphocytic infiltrations, proliferation of connective tissue, thrombi in small arteries and arterioles, and micro-extravasations within the spinal cord parenchyma [26] . The authors suggested that an autoimmunologic process was responsible for the vascular lesions in lupus myelitis. Other researchers demonstrated the presence of thrombosis, fibrinoid arteries, perivasculitis, spinal cord softening and peripheral white-matter degenerations at multiple spinal cord levels [27] . A more recent case report [2014] described the presence of intimal hyperplasia and obliteration of the small arteries and vasculitis (mononuclear cell infiltration and disruption of internal elastic lamina) in the affected case [28] .
There are suggestions that the pathological damage in lupus-associated myelitis might be less prominent after intensive immunosuppressive therapy [29] .
Magnetic Resonance Imaging
MRI is the modality of choice for the investigation of intramedullary lesions of the spinal cord. Both spinal and brain MRI are crucial in excluding spinal cord compression and in differentiating subtypes of acute demyelinating myelitis and other NPSLE disorders.
The detection of inflammatory lesion in the spinal cord can be facilitated by administering intravenous gadolinium on a T1-weighted image. However, the typical MRI appearance of ATM can be seen as a high intensity lesion detectable on a T2-weighted image, indicative of interstitial inflammation.
Under MRI, the affected spinal segments are described as "short" or "transverse" if less than 2-3 vertebral body segments are affected whereas "long" or "extensive" lesions involve more than 3 vertebral bodies. Both multiple sclerosis (MS) and neuromyelitis optica (NMO) may resemble ATM in its presentation. According to Weinshenker BG and co-workers[30], the involvement of more than three vertebral bodies was more common in NMO and helped to differentiate NMO from MS. 
Therapy and management
Thus far, the management of SLE-associated ATM has been mainly translated from treatment of 7 SLE and that of idiopathic inflammatory myelitis. During the acute phase, treatment is aimed to suppress the inflammatory process and stop any disease progression. Longer-term goal is aimed to prevent cord damage or loss of function.
Intravenous pulse methylprednisolone (0.5 to 1 g/day for 3 days) and cyclophosphamide (800 to 1200 mg/m 2 administered as a single pulse dose) are commonly used in the first line management of SLE[45] with major organ involvement and in idiopathic ATM [46] . There is evidence that the additional cyclophosphamide improves the efficacy [47] , and is therefore recommended by the EULAR task force [48] . Plasma exchange (PE) is sometimes used in the treatment of severe After the induction therapy with high dose intravenous glucocorticoid and cyclophosphamide, most patients are maintained on azathioprine, methotrexate, mycophenolate, or oral cyclophosphamide with or without low dose steroid [16] . Maintenance immunosuppressive treatment is usually recommended for 3 or more years although the optimal duration of maintenance therapy is yet to be defined. In cases of SLE with NMO, at least 5 years maintenance therapy is recommended[54].
The use of anticoagulation in SLE-associated ATM will need to be considered case by case. APL is thought to play a role in SLE-related ATM as evidenced by several pathological studies [25, 26, 28] and a large prospective study [35] . The use of anti-platelet and/or anticoagulation therapy is recommended for NPSLE related to antiphospholipid antibodies, and also for the management of ischemic optic neuropathy and refractory myelopathy [48] . The use of anticoagulant may be superior to anti-platelet therapy for secondary prevention of arterial event, as suggested by the EULAR task force [48] . However, in a review of 70 cases of SLE-associated ATM, Katsiari et al reported that they were unable to demonstrate any benefit of anticoagulation in SLE-associated ATM[55]. This study was limited by the relatively small sample size, retrospective design, and that the three subtypes of aPLs and their titers were not measured concurrently. It has been suggested that the presence of more subtypes and a higher titer of aPL may predispose to more thrombotic damage [35] , thus making the use of anticoagulant more favorable. However, both subdural hematoma and spinal cord bleeding have been reported in lupus-related myelopathy [27] , it is therefore important to weigh any pros and cons regarding anticoagulation therapy [48] . We may , while the other two women recovered well. In another case report, Nasir and colleagues[61] described a 48-year-old woman who experienced 19 attacks of myelitis during her 13-year history of SLE; all attacks had occurred without any other signs of lupus activity. She responded well to pulse methylprednisolone earlier on but less so in her later attacks.
Unfortunately, she became paraplegic after her last attack; a trial of rituximab had no benefit. 
Conclusion

